Ataluren for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene

Highly specialised technologies guidance
Reference number: HST22
Published: 22 February 2023

Evidence

Supporting evidence

Evaluation report
Evaluation consultation committee papers (PDF 9.53 MB)

Published:

22 February 2023
Final evaluation committee papers (PDF 2.27 MB)

Published:

22 February 2023